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Addressing the uncertainties in assessing health risks from cosmic ray heavy ions is a major scientific challenge
recognized by many previous reports by the National Academy of Sciences (NAS) and the National Council on
Radiation Protection and Measurements (NCRP) advising the National Aeronautics and Space Administration
(NASA). These reports suggested a series of steps to pursue the scientific basis for space radiation protection,
including the implementation of age and sex dependent risk assessments and exposure limits appropriate for a
small population of radiation workers, the evaluation of uncertainties in risk projections, and developing a
vigorous research program in heavy ion radiobiology to reduce uncertainties and discover effective counter
measures. The assessment of uncertainties in assessing risk provides protection against changing assessments of
risk, reveals limitations in information used in space mission operations, and provides the impetus to reduce
uncertainties and discover the true level of risk and possible effectiveness of countermeasures through research.
However, recommendations of a recent NAS report, in an effort to minimize differences in age and sex on flight
opportunities, suggest a 600 mSv career effective dose limit based on a median estimate to reach 3% cancer
fatality for 35-year old females. The NAS report does not call out examples where females would be excluded
from space missions planned in the current decade using the current radiation limits at NASA. In addition, there
are minimal considerations of the level of risk to be encountered at this exposure level with respect to the un
certainties of heavy ion radiobiology, and risks of cancer, as well as cognitive detriments and circulatory dis
eases. Furthermore, their recommendation to limit Sieverts and not risk in conjunction with a waiver process is
essentially a recommendation to remove radiation limits for astronauts. We discuss issues with several of the NAS
recommendations with the conclusion that the recommendations could have negative impacts on crew health
and safety, and violate the three principles of radiation protection (to prevent clinically significant deterministic
effects, limit stochastic effects, and practice ALARA), which would be a giant leap backwards for radiation
protection.

1. Introduction
A recent US National Academy of Science (NAS) report (National
Academy of Sciences 2021) advocates the implementation of a simpli
fied effective dose limit of 600 mSv for all astronauts, withdrawing from
the age and specific limits used since 1990 at NASA. The objective of this
recommendation is stated as a means to allow equivalent flight oppor
tunities for males and females of different ages. However, there is
minimal discussion of what flight limitations in the current framework
and in the near-term exist for female astronauts or what new possibilities

are opened for females by the proposed change. The stated charge to the
NAS listed in the report (National Academy of Sciences 2021) suggests
that non-cancer risks should not be considered, however, we discuss
extensive evidence that risk limits for cancer fatality likely have a large
bearing on the occurrence of radiation induced non-cancer risks. In this
report we caution several of the recommendations in the NAS report and
describe extensive over-sights in relation to crew safety by their
recommendations.
In space astronauts are exposed to high energy protons and heavy
ions that make up the galactic cosmic rays (GCR), trapped protons and
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electrons in low EARTH orbit (LEO), and infrequent solar particle events
(SPE) comprised largely of medium energy protons. Secondary radia
tion, including high linear energy transfer (LET) recoil nuclei from
neutrons are produced in shielding and tissues. NASA currently uses a
radiation limit of 3% cancer fatality risk evaluated at the 95% confi
dence interval as a limit to career exposures. In addition, limits are used
to avoid clinically significant deterministic or non-cancer effects to the
skin, lens of the eye, central nervous system (CNS) and the circulatory
system (See discussion below for details).
Cancer risk varies with age at exposure, health history, ethnicity,
lifestyle choices, and sex. This leads to a difference in effective doses to
reach an equal projection of lifetime risk for individuals or, equivalently,
to different lifetime risks for a given dose. The risks of breast, ovarian
and uterine cancer coupled with a known higher risk of radiationinduced lung cancer found in epidemiology studies, increases the risk
of females compared to males in projection models (Cucinotta et al.,
2013a; Cucinotta et al., 2013b; Cucinotta, 2014; Cucinotta, 2015;
Cucinotta et al., 2015; Cucinotta et al., 2016; Cacao et al., 2016; Cuci
notta et al., 2017; Cucinotta and Cacao, 2017; Cucinotta et al., 2018;
Cucinotta et al., 2020a; Cucinotta et al., 2020b). In addition, the longer
lifespan for females compared to males leads to an additional lifetime
radiation risk of about 10% for never-smokers independent of tissue
sensitivity to radiation. Furthermore, past occupational radiation ex
posures (space missions, aviation, medical exposures related to flight
duties) will also post a difference by affecting future space mission as
signments. This last difference reduces the importance of an equivalent
dose limit independent of age and sex. For example, two female astro
nauts of the same age, one with a prior International Space station (ISS)
mission and the another without, would have different limits for a lunar
or Mars mission.
The NAS committee recommended 600 mSv effective dose limit is
based on a 2012 NASA Space Cancer Risk (NSCR) model developed by
Cucinotta (Cucinotta et al., 2013a; Cucinotta et al., 2013b; Cucinotta,
2014) of the median estimate of the dose for a 3% risk of exposure
induced death (REID) from cancer for 35-year old females. In-fact, the
more recent versions of NSCR model suggest the possibility of a much
higher risk than 3% fatality at 600 mSv for 35-y old females (Cucinotta,
2015; Cucinotta et al., 2015; Cucinotta et al., 2016; Cacao et al., 2016;
Cucinotta et al., 2017; Cucinotta and Cacao, 2017; Cucinotta et al.,
2018; Cucinotta et al., 2020; Cucinotta et al., 2020). As described in this
present report the NAS commitee also did not consider heavy ion and
high LET neutron experiments that suggest important contributions
from non-targeted effects (NTE), which include bystander effect,
genomic instability and tissue microenvironment changes, in cancer
risk, a large relative risk (RR) or relative biological effectiveness (RBE)
for breast cancers compared to gamma-rays, and evidence for radiation
risks of circulatory diseases and cognitive detriments. The NSCR-2012
model does not account for qualitative differences between high- and
low-LET radiation that result due to increased complexity of DNA
damage and oxidative stress at high LET, and the resulting differences in
biochemical signaling in relation to disease development and progress.
The large number of open radiobiology issues are largely minimized or
not discussed in the NAS report (National Academy of Sciences 2021),
which relies almost entirely on discussion of gamma-ray and X-ray
epidemiology studies. It is well known that microscopic energy deposi
tion from heavy ions leads to both quantitative and qualitative differ
ences in biological effects compared to gamma-rays and X-rays (see
discussion below).
The NAS report suggests that a waiver process should be developed
for space exploration missions that would exceed the recommended
effective dose limit (National Academy of Sciences 2021). A main
conclusion of our critique of the NAS report is that we find that the
recommendations of a 600 mSv limit, irrespective of the corresponding
risk and its uncertainty, when combined with a waiver process has the
effect of removing radiation limits for astronauts. The NAS recommen
dation contradicts substantially past NAS (NAS 1970; NAS 1996; NRC

2008; NRC 2012; NAS-IOM 2001; NRC 1998) and NCRP recommenda
tions (NCRP 1989; NCRP 2000; NCRP 2006; NCRP 2014; NCRP 1997;
NCRP 2010) as described below. An unstated assumption made in the
recommendation of waivers is that they are issued by NASA. Our opinion
is that this is fundamentally unethical, since it allows NASA to decide
that an astronaut may be exposed to any quantity of radiation, in other
words, it creates a mechanism whereby NASA can potentially allow
significant harm to an employee. The only ethical way to proceed with a
waiver is if it is granted by an authority independent of the employer and
the employee that has examined the interest of all individuals affected,
as is done by Institutional Review Boards.
Space missions have a low aggregate risk for loss of crew (LOC), as
estimated by NASA to be less than 1 in 270 (Cucinotta et al., 2013b;
Aerospace Safety Advisory Panel 2013). The actual so-called accident
occurrences in the Apollo and Space Transportation System (STS) (space
shuttle) programs have led to an astronaut mortality of ~1.2% for all
NASA programs to-date, with the International Space Station (ISS)
incurring no accidents since its start in 1998. The average life-loss for an
astronaut of 40-y age at exposure from a radiation induced cancer is
estimated at about 15 years for gamma-rays and expected to be higher
for heavy ions based on animal studies (Cucinotta, 2014; Cucinotta
et al., 2020a), or about 2.5 times less than an estimated ~40 life-loss
years for a during mission LOC. Using the ratio for differences in
average life-loss and considering a 4–6- person crew size, suggests that a
comparable risk basis for a during-mission LOC design criteria to REID
limit would be a 1–10 ratio. On this basis, the 1 in 270 aggregate risk for
during mission LOC is then quite similar to the current 1 in 33 radiation
cancer fatality limits at NASA, while an aggregate risk of 1 in 750 sug
gested to be achievable through smart investments recommended by the
Aerospace Safety Advisory Panel (ASAP) (Aerospace Safety Advisory
Panel 2013) would suggest a lower limit on acceptable radiation fatality
risks. These arguments suggest a lower radiation limit should be a future
goal for space radiation protection. NCRP Report No. 98 (NCRP 1989)
noted that radiation risks should not be ignored, but should be limited
because of a high LOC risk. Other considerations are the additional ra
diation non-cancer mortality and morbidity risks (2–3-fold higher than
mortality risk), and the ethical consideration that values life at all ages,
as opposed to considerations of LOC during the mission alone.
The NAS recommendation to set limits based on the highest-risk
sensitive individual means that older astronauts, who would incur a
lower risk for exposure to the same quantity of radiation, would be
eventually excluded from renewed participation in missions. The
exclusion of experienced astronauts would seem to significantly increase
the risk to mission objectives, as well as to the safety of crew members on
such missions.
In this Commentary, the authors evaluated the main recommenda
tions of the recent NAS report (1) through the following eight targeted
questions:
Q1) Is the premise that female astronauts are limited in mission opportu
nities compared to male astronauts valid in the current decade?
Q2) Is there valid new information to suggest radiation induced lung
cancer risk is not higher in females than males? Do low dose and low
dose-rate reactor worker studies have any relevance for predicting
radiation risk to astronauts?
Q3) Issues in estimating the risks of breast, ovarian, and uterine cancers
from heavy ions were not discussed in the NAS Report, along with the
sex dependence of RBE for radiation-induced lung cancer. How could
this information influence a limit or waiver process?
Q4) Should uncertainties in space radiation risk assessments be down
played or ignored before risks limits are set and sufficient knowledge
of heavy ion radiobiology effects on cancer, cognition and circulatory
diseases are obtained? Are the limits for non-cancer effects violated by
the NAS Recommendation?
Q5) The NAS Report did not consider differences in risk estimates between
the 2012 version of the NSCR (Cucinotta et al., 2013a; Cucinotta
60
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et al., 2013b; Cucinotta, 2014), and more recent versions of NSCR
(Cucinotta, 2015; Cucinotta et al., 2015; Cucinotta et al., 2016;
Cacao et al., 2016; Cucinotta et al., 2017; Cucinotta and Cacao,
2017; Cucinotta et al., 2018; Cucinotta et al., 2020a and 2020b).
What are the implications of these differences?
Q6) What would be alternate solutions for near and mid-term goals for
equality of flight opportunities for astronauts of different ages and sex
in-light of anti-discriminatory government legislation, such as HIPAA*
privacy laws, and GINA** regulating the use of individual personal
information?
Q7) Is a waiver process necessary when NASA management has the au
thority to increase limits to higher risk or exposure level? Is it ethical
for a waiver to be issued by an employer that permits an employee to
incur potentially life-threatening risks?
Q8) What are risk communication processes, especially for missions
involving large radiation health risks?

are possible limitations for female compared to male astronauts, espe
cially if past ISS or lunar missions had occurred for an individual.
However, the blood forming organ (BFO) limit could limit both male and
female astronauts depending on shielding and SPE considerations. For a
Mars mission projected at 900–1100 days, the current limit system and
the proposed 600 mSv limit would likely exclude both male and female
astronauts until risk projection uncertainties are significantly reduced
and effective countermeasures are discovered.
Q2) Is there valid new information to suggest radiation induced lung
cancer risk is not higher in females than males? What impact do low dose and
low dose-rate reactor worker studies have for predicting radiation risk to
astronauts?
The NAS Report describes studies besides the Japanese Life Span
Study of atomic bomb survivors (LSS) (Brenner et al., 2018; Grant et al.,
2017) that provide differential results on lung cancer risks between
males and females, with the main so-called “new” findings based on the
International Study of Reactor Workers (INWORKS) (Leuraud et al.,
2015; Richardson et al., 2015; Richardson et al., 2018). The LSS study
provides information on breast, ovarian and uterine cancer risks and
demonstrated a higher risk of lung cancer in females compared to males.
Older studies on medical patients exposed at much high doses were
considered earlier in NAS and NCRP reports advising NASA on radiation
risks. The average organ doses in the LSS are about 250 mSv, while in the
INWORKS the average organ doses are estimated at 20 mSv, but for
chronic irradiation often over more than 10 years of employment. We
find that the INWORKS study of cancer deaths in reactor workers in the
US, Canada and Europe provides useful information for other exposed
groups at lower doses of low LET radiation, but not for astronauts and is
much less useful than the LSS for the following reasons:

*Health Insurance Portability and Accountability Act of 2000 and its
Modifications
**Genetic Information Non-Discrimination Act of 2018.
2. Discussion of NAS recommendation #1
Recommendation #1: NASA should proceed with the proposed
approaches to revising the space radiation health standard. As
proposed by NASA, the agency should:
• Apply a single space radiation standard to all astronauts;
• Utilize the most protective approach in setting the space radi
ation standard;
• Set the standard as a dose limit; and
• Utilize the mean value of the risk distribution based on 3% risk
of exposure-induced death.

1) The doses in the INWORKS are predominantly far below a single ISS
mission dose (~90% of the INWORKS population) with less than 3%
of the population studied near the NAS recommended dose limit of
600 mSv (Table 1). In contrast the LSS has a significant number of
persons with organ doses above 100 mSv (> 50%) of relevance to ISS
or lunar missions, and in the region of the recommended effective
dose limit (Table 1).
2) The low doses of the INWORKS are such that on average a worker
received an additional single electron track per cell per year from a
penetrating gamma-ray, which has almost no relevance to heavy ion
exposures where all the cells in the path of a single heavy ion
simultaneously receive large doses (0.1 to several Gy dependent on Z
and E) within 10− 16 s. In contrast the LSS cohort received larger
doses (many with doses of 0.1 to several Gy) almost instantaneously
(< 1 s), albeit the spatial distribution of ionizations within a cell
would be very different compared to ions (Fig. 1). The types of DNA
damage events (Goodhead and Nikjoo, 1989) would be similar in the
INWORKS and LSS. However, the number of such events at the lower
doses of the INWORKS presents statistical limitations relative to

Q1) Is the premise that female astronauts are limited in mission oppor
tunities compared to male astronauts valid in the current decade?
We find very few scenarios where female astronauts are limited in
mission opportunities compared to male astronauts with the current risk
limits at NASA, with none likely in the next 10–15 years. State-of-the-art
uncertainty analysis, has shown that female astronauts can participate
on several ISS Missions with a total duration of 2-years if their first
mission is at age 35 years (Cucinotta, 2014). Also, lunar missions of up to
6-months would be within the current standards (Cucinotta et al., 2018),
and certainly a combination of an ISS and a lunar mission both of up to
6-month is possible. Some assumptions are needed on the balance of
number and length of missions (ages, between missions, etc.). ISS mis
sions are limited in the number of persons on-board with twelve persons
participating in 6-month missions per year or six persons on 12-month
missions or some combination. Crew assignments are divided between
NASA and other national space agencies with NASA enjoying typically 2
crew persons per crew rotation. We also need to consider how many
years of training are involved between missions, which is typically 3–5
years. Under the assumption of radiation risk declining with age of
exposure, ISS durations longer than 2 years are possible. Timelines for
lunar missions and their potential durations are often modified, however
at this time we expect the first lunar missions would be of short duration
(< 30 days) and no earlier than 2028. No funding for a lunar base needed
for a long-stay has been allocated by US Congress, and a lunar base
would likely delay a Mars mission by many years because of financial
constraints.
Therefore, in the current decade there are no limitations for female
astronauts until total times on ISS missions longer than 2 years are
considered, which has not occurred in the past for either male of female
astronauts, and female astronauts would likely be able to participate in
ISS missions and several short lunar missions. Another scenario is a
deep-space mission such as a 1-year Mars swing-by mission. Here there

Table 1
Comparison of doses in INWORKS to LSS. The INWORKS study is only 9%
female while the LSS is 60% female and doses more distributed near 600 mSv
(Grant et al., 2017; Brenner et al., 2018; Leuraud et al., 2015; Richardson
et al., 2015; Richardson et al., 2018).
Dose range, mSv
< 10
10–50
50–100
> 100
<5
5 to 500
500 –1000
> 1000

61

Number persons

% of cohort

INWORKS (reactor workers)
115,915
70%
36,470
21
10,029
5.8
10,667
6.2
LSS (Japanese A-bomb survivors)
35,978
44.9%
39,031
48.7
3136
3.9
2060
2.6

Approximate %- females
7%
2.1
0.58
0.62
26.9%
29.2
2.3
1.5
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Fig. 1. Dose deposited in 20 nm voxel representative of a small segment of DNA with several hundred base-pairs from (left panel) 20 keV electron produced by
gamma-rays at ~1 mGy, (center panel) 20 keV electrons from gamma-rays at ~50 mGy, and (right panel) single 56Fe ion at 1 GeV/u. Calculations are made with the
RITRACKS code (Plante and Cucinotta, 2008). For the average worker dose of 20 mGy in the INWORKS, single electrons would occur in each cell about once per year.
Each heavy ion creates 100 s or more electrons in a directly traversed cell through ionization along its path nearly instantaneously (< 10− 16 s). For LSS, 10 to several
100 electrons could occur in each cell almost instantaneously (< 1 s), which is more representative of ions although important differences in the spatial distribution of
ionizations occur. The track core of the ion traversal produces a much higher voxel dose (105 Gy) than gamma-rays, even for absorbed doses of gamma-rays as large
as several hundred Gy (> 100,000 mGy) leading to qualitative differences in damage denoted as clustered DNA damage (Goodhead and Nikjoo, 1989). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3)
4)
5)

6)

7)

8)

background cancer rates, and the presence of multiple DNA damage
events simultaneously in LSS exposures is suggested to lead to dif
ferential biochemical reactions in response to this damage compared
to INWORKS, with such reactions more reflective of the burst of
damage in cells following heavy ion traversals.
The INWORKS study is less than 9% females compared to the LSS
study which has ~60% females.
The number of persons in the INWORKS is larger than the LSS,
however the number of person-years (PY) used in statistical analysis
is similar in both studies (~2.5 million).
The NSCR model uses cancer incidence data for its low LET radiation
baseline, while INWORKS reports only cancer mortality data. The
LSS reports both incidence and mortality. Cancer mortality rates
continue to decline (Siegel et al., 2021) in the U.S., and the NSCR
model uses the most up-to-date information to convert incidence to
mortality based on the current U.S. population as recommended by
the NAS BEIR VII Report (BEIR, 2006), and provides a tool to explore
this conversion for high LET radiation and healthy workers.
The LSS and INWORKS both must consider birth cohort effects;
however, these effects are more straight-forward in the LSS study
because of the single exposure date, while in the INWORKS study
persons of the same age at exposure often have different birth years
separated by years to several decades.
The LSS provides important information on age at exposure, attained
age or latency for tissue specific cancers not provided by INWORKS
at this time, allowing investigation of both excess additive risk (EAR)
and excess relative risk (ERR) models using the LSS data.
The INWORKS does not provide accurate information on a dose-rate
modifier (e.g. dose and dose-rate reduction effectiveness factor
(DDREF)) because the chronic exposures involved both low dose-rate
and protraction effects, and there is no appropriate comparison
group with acute exposures. In contrast DDREF estimates, although
somewhat uncertain, have been made from the LSS through study of
the shape of the dose response curves (BEIR, 2006; Hoel, 2015), with
values estimated in the range of 1.2–3, which are considered in the
NSCR model’s Bayesian analysis (Cucinotta et al., 2017). Protraction
effects would not be important for space missions because of their
limited duration and dose-rate effects distinct from low LET radia
tion (Cucinotta et al., 2016; Schimmerling and Cucinotta, 2006) due
to small number of heavy ion traversals per cell (Cucinotta et al.,
1998).

Q3) Issues in estimating the risks of breast, ovarian, and uterine cancers
from heavy ions were not discussed in the NAS Report, along with the possible
sex dependence of RBE for lung cancer. How would this information influence
a Sievert limit or waiver process for females?
The NAS report makes no discussion of issues related to assessing
risks of female specific cancers (breast, ovarian and uterine corpus) and
differences in RBE observed in male and female mice. These issues are
important for understanding uncertainties for heavy ions and other high
LET radiation. Storer et al. (Storer et al., 1988) examined gamma-ray
exposures in 6 strains of mice, and showed that relative risk (RR) esti
mates adequately represented the RR in the atomic bomb survivors for
several types of cancer, including lung, mammary (breast), liver and
leukemia. This study along with matching the tumor types in mice and
humans provides important justification for exploring RBEs in mice for
several tissues. We next summarize published studies that suggest there
are important open issues related to understanding risks and RBE’s for
female astronauts exposed to high LET radiation.
Secondary neutrons in space or on the Martian surface have a broad
energy range (Kim et al., 2014; Kim et al., 2015). Older studies of
neutron effects at high LET provide some information of relevance to
NASA. Fission neutrons (E < 2 MeV) do not adequately represent
neutron energies in space, however they provide information on the
largest RBE’s observed. Cyclotron neutrons with energies up to 20 MeV
are more representative of neutrons to be encountered in space. Coggle
(Coggle, 1988) studied the RBE for lung adenomas and adenocarcinoma
in 3-month-old male and female SAS/4 albino outbred mice and found
that the RBE for cyclotron neutrons (mean neutron energy 7.5 MeV)
were 2-fold higher in female mice compared to male mice with an
estimated RBE for females and males compared to higher X-rays doses of
8.6 ± 3.6 (female) and 4.7 ± 1.8 (male). RBE estimates against a lower
dose of X-rays (0.1 Gy) were estimated as 86 for females and 47 for
males. Of note is that the RBE for cyclotron neutrons is found as 4-times
lower than fission neutrons in other studies. Unfortunately, NASA has
not funded studies of RBE for lung cancer comparing male to female
mice with identical fluences of heavy ions. In contrast, we note that
funding by the National Institutes of Health (NIH) for animal research
requires nearly all studies to use both male and female animals.
Exceedingly large RBE’s are reported for fission neutron induced lung
tumors in female RFM and Balb/C mice of > 283 and 60, respectively
(Ullrich et al., 1976; Ullrich et al., 1977), however no comparisons to
male mice were made.
62
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In Balb/c mice (Ullrich et al., 1977) the RBE for low dose fission
neutrons was estimated at 33 for mammary tumors. Several studies of
mammary tumors in rats estimated RBEs as large as 100 (Fry, 1981;
NCRP 1990). These values are much larger than the average RBE across
various solid tumors in mice. However, the fraction of adenocarcinomas
in different strain of rats is generally < 15%, with a much larger fraction
of benign fibroadenomas occurring, which are less useful for considering
risks in humans.
An important issue in understanding the risks of mammary cancers
after high LET radiation is the influence of damage, including cancer
induction, to the mouse ovary. Ovarian tumors in mice are believed to
occur when extensive oocyte cells are killed which results in elevated
release of gonadotrophins from the perturbed pituitary-gonad axis
(NCRP 1990). A clear threshold dose for induction of ovarian tumors by
gamma-rays occurs at about 100 mGy. Damage to the ovary, including
changes to hormonal regulation, is suggested to reduce mammary tumor
induction at higher doses of fission neutrons potentially reducing RBE
estimates because of the downward curvature introduced at higher
doses (Ullrich et al., 1977; Fry, 1981; NCRP 1990).
Because no human data for cancer risk from heavy ions exists,
experimental findings on mechanisms for heavy ions and elucidating
both qualitative and quantitative differences with low LET radiation are
vital to space radiation risk assessment. Non-targeted effects (NTE) are
an important issue in estimating low dose space radiation cancer risks
because they alter the shape of the dose response for tumor induction,
which increases RBE estimates, and suggest a mechanism for tumor in
duction distinct from DNA damage and mutation. Barcellos-Hoff and coworkers in a series of elegant experiments with a chimera model of
mammary tumor induction by radiation (Illa-Bochaca et al., 2014;
Omene et al., 2020) has demonstrated NTE, including differences in the
protective immune infiltration of myeloid cells between low LET and
heavy ions. Protective myeloid cells are shown to be inhibited with
heavy ions, a mechanism not observed in gamma-ray irradiation, lead
ing to rapid progression of tumors. Spaceflight has been shown to have
differential inflammatory effects on crew and experimental systems in
missions of duration of few months (Akiyama et al., 2020; Gueguinou
et al., 2009), and thus the influence of NTE related to immune response
and synergies with other flight factors should be a concern for long-term
missions.
The risk for ovarian and uterine cancers for heavy ions has not been
well studied, with no estimates of RBE’s reported. A recent report using
12-week-old C57BL/6 exposed to 0.5 Gy Fe particles (Mishra et al.,
2018) shows a large increase risk of ovarian cancers, which were diag
nosed as tubular adenomas or mixed tubular adenoma/granulosa cell
tumors.
Q4) Should uncertainties in space radiation risk assessments be down
played or ignored before risks limits are set and sufficient knowledge of heavy
ion radiobiology effects on cancer, cognition and circulatory diseases are
obtained? Are the limits for non-cancer effects violated by the NAS
Recommendation?
Permissible exposure limits are based on the principle of limiting
stochastic risks to a level that it accepted based on ethical consider
ations, and the societal value of the endeavor leading to risk (Schim
merling, 2010). There are many open questions and large uncertainties

in our ability to predict the GCR risk at a larger exposure level of 600
mSv or similar levels, which suggest that it’s premature to accept such a
limit, and as noted above the current limit system poses no barriers for
multiple missions by female astronauts in this decade and perhaps
longer into the future. Here we point out several areas that suggest the
risk is poorly defined and requires further investigation to i) decide if the
fatality risk for exploration missions is below 3% and ii) the level of
morbidity risk for cancer, circulatory diseases and cognitive detriments
at this exposure level. The goal of our summary is not to make an
extensive review, but to point out several major questions that been
identified through research but have not be adequately addressed.
NTEs include bystander effects where cells traversed by heavy ions
transmit oncogenic signals to nearby cells, genomic instability in the
progeny of irradiated cells and tissue microenvironment changes related
to cancer development. NTE have been shown to impact initiation,
promotion and progression stages of tumorigenesis at low doses of high
LET radiation (Illa-Bochaca et al., 2014; Omene et al., 2020; Maxwell
et al., 2008; Kadhim et al., 2013; Lorimore et al., 2003; Barcellos-Hoff
and Mao, 2016; Hada et al., 2014; Nagasawa and Little, 1992; Belyakov
et al., 2005; Chang et al., 2016). Initiation processes impacted by NTEs
include chromosomal exchanges, sister chromatid exchanges, gene
mutation, and neoplastic transformation, and shown to lead to a
supra-linear dose response at low doses when less than one ion traverses
a cell nucleus. A similar functional response provided an optimal global
fit to the Harderian gland tumor study with several heavy ions (Chang
et al., 2016; Cucinotta et al., 2018). Mechanistic studies of NTE’s and
dose response studies with heavy ions and high LET radiation at low
fluence, where particle traversals are less than one particle per cell,
suggest a deviation from linearity and increase in RBE which are
important implications for GCR cancer risk assessments. A deviation
from linearity would reduce the effectiveness of shielding.
As noted by Cucinotta et al. (Cucinotta et al., 2015) several studies
(Fry, 1981; Fry et al., 1985; Alpen et al., 1993; Weil et al., 2009; Weil
et al., 2014; Grahn et al., 1992; Imaoka et al., 2007; Trani et al., 2010;
Datta et al., 2013; Wang et al., 2015) have suggested that high charge
and energy (HZE) particles and neutrons could produce more aggressive
and lethal tumors compared to tumors produced by low LET radiation or
background tumors, which is a qualitative difference not accounted for
in current risk estimates. Table 2 summarizes these findings from ani
mal studies with HZE particle beams or fission neutrons. For low LET
radiation there is an implicit assumption made by epidemiology models
that the tumors induced by radiation are similar to background tumors
in a population. This assumption is consistent with the relative (multi
plicative) risk model, and also based on lack of information to make an
alternative assumption. Using the sensitivity analysis method described
in recent reports (Cucinotta, 2014; Cucinotta et al., 2015), suggests that
increases in tumor lethality for HZE particle and neutrons compared to
background or low LET tumors as suggested by animal studies could
substantially increase REID and uncertainty estimates. These are
important findings on more aggressive tumors produced by high LET
radiation, while not conclusive at this time, these possibilities based on
current evidence still need to be understood before long-term explora
tion missions are conducted.
The NAS recommendation (National Academy of Sciences 2021)

Table 2
Summary of qualitative differences in tumor response for HZE particles compared to γ-rays or control tumors in mice.
Tumor model

Qualitative difference observed

Harderian Gland Tumors in B6CF1 female mice (Chang et al.,
2016; Fry et al., 1985; Alpen et al., 1993)
Hepatocellular carcinoma in male C3H/HeNCrl mice (Weil et al.,
2009; Weil et al., 2014)
Lung tumor in C57BL/6 mice (Wang et al. 2015)
Mammary tumors (Illa-Bochaca et al., 2014; Omene et al., 2020;
Imaoka et al., 2007)
Intestinal tumors in APC Min/+ mice (Datta et al., 2013)

Dose response for Fe particles was qualitatively different from γ-rays.
Dose response for Si and Fe particles was qualitatively different from γ-rays. Incidence of metastatic tumors
significantly increased with Si and Fe particles compared to γ-rays or simulated solar protons.
More aggressive lung tumors observed for Si particles compared to low LET or control tumors.
Differences in mammary tumor types comparing heavy ions to low LET radiation with more aggressive tumors
observed. Heavy ions inhibit protective myeloid cells leading to rapid progression of tumors.
Heavy ions increased tumor multiplicity and grade compared to protons or γ-rays.
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does not consider the impacts of a 600 mSv limit on the risks of deter
ministic effects (tissue reactions) from GCR and SPEs. NASA has
implemented a preliminary dose limit to the CNS for heavy ions and
other high LET radiation of 100 mGy. CNS risks would be deterministic
in nature, and therefore risks are to be avoided and not limited under a
fundamental principle of radiation protection. The 100 mGy limit was
based on earlier studies of cognitive risks, while investigators continue
to document cognitive detriments at lower doses, including several
studies at 50 mGy (Britten et al., 2017; Cucinotta and Cacao, 2019;
Parihar et al., 2016; Parihar et al., 2015; Parihar et al., 2020; Raber
et al., 2016). The possibility that the CNS limit should be lowered to 50
mGy or even lower for heavy ions and high LET secondary radiation
would lead to the possibility that a 600 mSv limit would lead to either
in-mission or post-mission cognitive detriments. CNS risks would
include in-flight detriments of cognition, such as memory and perfor
mance detriments, and late effects, including advancement of the age of
Alzheimer’s disease (Liu et al., 2018) or increases in the incidence of
Parkinson’s disease (Azizova et al., 2020). Differential results are re
ported for differences in male and female cognitive responses in mice
after heavy ion irradiation, with B6D2F1 mice showing higher sensi
tivity for females (Raber et al., 2016) and C57Bl/6 mice showing higher
sensitivity for males (Parihar et al., 2020).
The translation of various experimental observations of cognitive
detriments in rodent models exposed to heavy ions to human risk is
complex. In a simplified approach the “Sievert” is the result after con
version of physical organ doses to biological equivalent organ doses, and
this conversion varies with health risk as described below for various
types of cancer. For CNS risks if a threshold dose of more than 100 mGy
of heavy ions occurs, the “Sievert” for space radiation is essentially zero
for space missions, including a Mars mission. However, if the threshold
is below ~50 mGy the threshold is likely exceeded. Therefore, the value
of a “Sievert” for cognitive risks is undefined until threshold doses and
RBE’s are determined (or alternative biophysical approaches to risks
assessment are created), and could be greatly above 600 mSv based on
several experiments reported recently (Britten et al., 2017; Cucinotta
and Cacao, 2019; Parihar et al., 2016; Parihar et al., 2015; Parihar et al.,
2020; Raber et al., 2016).
Circulatory risks from low dose radiation including to those in
Russian radiation workers (Little et al., 2012) and the LSS (Takahashi
et al., 2017) suggest a no threshold dose response model for overall risks
with differential results for the various components of the risk. However,
RBE values and DDREFs for circulatory risks have been sparsely studied.
Cucinotta and co-workers used the meta-analysis results for ischemic
heart disease (IHD) and cardiovascular disease (CVD) with the deter
ministic RBE model to estimate organ Gy-Eq dose and predicted that
circulatory disease risk would add 15–35% (dependent on age at
exposure and sex) of the total lifetime fatality risk over the cancer risk
alone (Cucinotta et al., 2017; Cucinotta et al., 2013b; Cucinotta et al.,
2020). For the LSS studies higher RR are found for females compared to
males (Little et al., 2012), however the meta-analysis of Little et al.
(Takahashi et al., 2017) did not consider sex differences on RR esti
mates. Using identical RR factors for males and females results in a
higher prediction for males for the U.S. population because of differ
ences in background rates of age specific IHD and CVD for males and
females.
Other lifetime risks to be considered are the increased risks of death
from non-cancer respiratory diseases found in the LSS study (Pham et al.,
2013) for doses of 1000 mSv and higher, which could be approached if
the RBE from GCR for this endpoint was high. Also, the results of low
GCR dose studies of cataract in astronauts (Cucinotta et al., 2001;
Chylack et al., 2009) suggest vision impairing opacities cannot be
excluded from occurring within a long mission (> 1 year) at higher lens
GCR doses than past Apollo, Skylab and STS missions. For a deep space
mission near solar minimum, the 600 mSv would allow some possibility
of exceeding the annual blood forming organ (BFO) limit of 500
mGy-Eq.

Q5) The NAS Report did not consider differences in risk estimates be
tween the 2012 version of the NSCR developed by Cucinotta et al. (Cucinotta
et al., 2013a; Cucinotta et al., 2013b; Cucinotta, 2014), and more recent
versions of NSCR (Cucinotta, 2015; Cucinotta et al., 2015; Cucinotta et al.,
2016; Cacao et al., 2016; Cucinotta et al., 2017; Cucinotta and Cacao,
2017; Cucinotta et al., 2018; Cucinotta et al., 2020; Cucinotta et al.,
2020). What are the implications of these differences?
Since 2012 several new versions of the NSCR model have been
developed and published by Cucinotta et al. (Cucinotta, 2015; Cucinotta
et al., 2015; Cucinotta et al., 2016; Cacao et al., 2016; Cucinotta et al.,
2017; Cucinotta and Cacao, 2017; Cucinotta et al., 2018; Cucinotta
et al., 2020; Cucinotta et al., 2020). Uncertainties considered in the
NSCR-2012 model include the physics of environments and radiation
transport in predicting organ exposures, low LET epidemiology, quality
factor (QF) and dose-rate modifiers represented by the DDREF, while
more recent versions consider the role of NTEs on QFs and higher
lethality of tumors at high LET. A review of some of the changes were
supported by the NASA external Research and Clinical Advisory Panel
(RCAP) in 2015 (NASA 2015) comprised of several of the members of
the NAS and NCRP review panels for the NSCR-2012 (NRC 2012; NCRP
2014). The main developments were:
i Replacing risk estimates based on RBEmax (RBE relative to low
dose or chronic gamma-rays) with estimates based on RBEacute
(RBE relative to acute gamma-rays for doses near 1 Gy). This
reduced uncertainties due to error avoidance from low dose or
chronic gamma-ray exposures, which are often ineffective, and
from using sparse gamma-ray data to estimate RBEmax that were
reported in heavy ion experiments. In this approach the QF has
two terms representing the so-called core and penumbra of ion
izations along an ions path. The core term because it involves
very large energy depositions from individual ions, is assumed
not to be modified by a DDREF.
ii Refining the NSCR Quality Factor (QF) to consider objective
determination of model parameters as recommended by NAS in
2012 (NRC 2012), and introducing a correlation of the QF and
DDREF using similar experimental data for QF parameter analysis
and revised Bayesian analysis of the probability distribution
function (PDF) of the DDREF.
iii Updating parameter estimates from heavy ion experiments pub
lished after 2012 (Chang et al., 2016; Suman et al., 2016) and
re-evaluation of cell (Cacao et al., 2016) and fission neutron ex
periments (Cucinotta et al., 2017) in QF parameter estimates.
iv Sensitivity study of higher lethality for high Z–high LET tumors in
conversion of incidence to fatality risk (Cucinotta, 2014; Cuci
notta et al., 2017).
v Predictions of circulatory disease risk in combination with cancer
risk using meta-analysis from Little et al. (Little et al., 2012) for
circulatory risks and RBE for non-cancer risks from NCRP rec
ommendations (NCRP 2000).
vi Introducing QF model with non-targeted effects for solid cancer
risks (Cucinotta and Cacao, 2017; Cucinotta et al., 2018; Cuci
notta et al., 2020a).
vii Updates to US population data for life-table and tissues specific
cancer risks to most recent (2018) available data from the Center
of Disease Control and Prevention (CDC).
The NSCR-2012 model developed an average QF for all solid cancers
and a separate QF for leukemia risk, with a resulting lower QF for leu
kemia compared to solid cancers. However, the development of tissue
specific QF for various solid cancer types and between males and fe
males was not addressed because of insufficient experimental data for
heavy ions.
The definition of a “Sievert” is distinct in the NSCR-2012 model from
that recommended by the NCRP (NCRP 2000). NSCR-2012 and more
recent versions use a track structure-based approach, with different
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Fig. 2. Panel A/D, probability distribution functions for fatal cancer for females (A), and males (D) comparing the older NSCR-2012 to the NSCR-2014 predictions
(Cucinotta et al., 2015). Panel B/E, probability distribution functions for REID by fatal cancer or with addition of circulatory disease risks and increased fatality from
high LET particles for females (B) and males (E). Panel C/F, predictions of the number of “safe days” in space to be below career exposure limits for REID for females
(C) and for males (F) using different assumptions on allowable uncertainties in the NSCR-2014 model without or with additional fatal risk contributors. . (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

parameter estimates for the QF for solid cancer and leukemia risk. The
NCRP recommends the use of radiation weighting factors or LET
dependent quality factors with no distinction between solid cancer and
leukemia risks. There are also different definitions in the NSCR-2012
definition compared to NSCR-2018, where the latter couples the QF to
the DDREF model and the underlying probability distributions for model
parameters. Thus, the duration of an exposure to GCR or SPEs leading to
600 mSv effective dose (i.e., Sieverts) is, to some extent arbitrary until a
specific definition of how to convert particle fluence to risk is made.
Risk estimates were made for ISS crew on 6-month followed by 1year missions near solar minimum (Cucinotta, 2014). These analyses
show a dependence on age for each mission length and solar cycle
conditions. Furthermore, several missions, including 1-year mission,
carry risks for female astronauts within the current radiation limits. As
such, with current limits, significant ISS opportunities will be likely for
female crew even with the assumptions of circulatory risk and increased
tumor lethality (Cucinotta, 2014).
For deep space missions the NSCR-2014 model made predictions
compared to NSCR-2012 and with the additional assumptions of
increased circulatory risk and higher tumor lethality estimates as shown
in Fig. 2. These estimates made for 1-year missions near solar minimum
with 20 g/cm2 aluminum shielding are relevant for lunar missions. On

the surface of the moon the GCR are reduced by 1/2, and detailed
analysis including estimates of NTE, shows female crews can participate
in several short duration lunar missions or a combination of 6-month ISS
mission and a short duration lunar mission.
For long-stay lunar missions that might occur in the next decade
(2030′ s) more detailed analyses would be needed for both female and
male astronauts.
For a Mars mission the cancer and circulatory disease risks could be
quite high as shown by predictions near average solar minimum con
ditions in Table 3 (reproduced from (Cucinotta et al., 2020a)). The
upper 95% confidence levels exceed 10% for both females and males of
different ages, and the morbidity risk for cancer above 20% in several
cases. The current NAS Recommendation is to allow these potentially
high risks through NASA using a waiver process.
Another factor not considered in the NAS report is that there is a
difference in the probability distribution of the %REID for different
types of space radiation exposures (trapped radiation, solar particle
events, solar minimum GCR, solar maximum GCR, GCR in LEO versus
deep space due to EARTH magnetic shielding, Mars surface), and for
different shielding materials. Heavy ions have a larger uncertainty
compared to solar protons. Heavy ion biological effectiveness peaks at
kinetic energies of few hundred MeV/u, which is an energy region

Table 3
Predictions of mean and 95% confidence intervals for cancer and circulatory disease risks for a 900-day Mars mission near solar minimum (Cucinotta et al., 2020a).
Age at exposure, y
20
40
60
20
40
60

%REIC (cancer morbidity)

%REID (cancer death)

Females U.S. average population
20.9 [7.04, 51.4]
9.74 [2.71, 21.9]
13.2 [3.65, 35.5]
7.59 [2.03, 20.3]
8.63 [2.22, 26.0]
5.91 [1.44, 17.8]
Males U.S. average population
12.7 [4.97, 29.3]
6.1 [1.96, 14.1]
9.28 [3.13, 22.4]
4.94 [1.18, 12.2]
6.26 [1.82, 16.0]
3.82 [0.89, 9.69]
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%REID (circulatory disease death)

%REID (combined probability of death)

1.16 [0.48, 2.26]
1.2 [0.51, 2.37]
1.23 [0.53, 2.49]

10.9 [3.45, 22.5]
8.8 [2.78, 21.0]
7.17 [2.3, 18.7]

1.48 [6.3, 2.93]
1.54 [0.66, 3.05]
1.62 [0.69, 3.19]

7.58 [3.38, 15.6]
6.49 [2.58, 13.6]
5.44 [2.06, 11.3]
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reduced substantially at solar maximum due to solar modulation, or in
LEO due to the EARTH’s magnetic field. Secondary neutrons carry a
large REID uncertainty and are produced in higher amounts for
aluminum shielding compared to water or polyethylene, and more
frequently on the lunar or Mars surface due to albedo neutrons. The use
of a 600 mSv limit does not consider the variation in uncertainty with
the specifics of the different kinds of space radiation exposure.
Q6) What would be alternate solutions to the NAS Recommendation for a
goal for equality of flight opportunities for astronauts of different ages and
sex, in-light of anti-discriminatory government legislation, such as HIPAA
privacy laws, and GINA regulating the use of individual personal
information?
An important issue in minimizing space radiation risk is the conun
drum of ignoring the science, which suggests higher risks for females,
large uncertainties in predicting risks, and a variety of factors that would
possibly enable medical staff to identify astronauts of low or high ra
diation sensitivity. The major part of the solution to the conundrum is to
complete research studies needed to fully understand radiobiology of
the issues identified above including risks of breast, ovarian and uterine,
lung and other cancers, the role of non-targeted effects, the quality of
HZE particle tumors compared to low LET radiation, cognitive risks, and
circulatory disease risk.
There are several areas of risk prediction that could be pursued on an
individual basis through a medical program, including those related to
family history of cancer and genetic screening (NCRP 2010; Locke and
Weil, 2016), however the science in these areas is incomplete at this
time. The NIH maintains a policy that sex as a biological variable (SABV)
is of utmost importance in clinical care and research (Clayton, 2018;). In
the LSS (Brenner et al., 2018) the age of menarche is shown to have a
profound effect on radiation breast cancer risk in women with a 3-fold
decrease in risk for exposures at age 30 between ages of menarche of
12 and 18 years. The study of tumor induction in mice (Storer et al.,
1988) following gamma-ray radiation suggests susceptibility is inher
ently tied to predisposition to specific types of cancer. However, two
limitations occur here. First as described above high LET radiation has
been shown to use distinct mechanisms of cancer initiation and pro
gression compared to low LET radiation. Secondly, there are a large
number of cancer types that contribute to overall radiation cancer risks,
including lung, breast, liver, stomach, colon, bladder, brain, and leu
kemias. Family history for one specific cancer type may have only a
small impact on overall risks. The science of genetic factors that may
increase or reduce radiation risks from heavy ions and other high LET
radiation is incomplete at this time, while tissue specific factors may
have only a small impact on overall risk. Genetic factors related to DNA
damage and immune responses and several other hallmark processes
that span several tissues should be a focus of research studies on genetic

susceptibility with heavy ions.
We have argued that the current radiation limits, which are based on
a 3% fatality risk and assessment of uncertainties in the projection at the
95% confidence level, is sufficient to allow most flight opportunities for
female astronauts in the current decade and possibly well into the next
decade. The basic conundrum of balancing opportunity and risk for in
dividuals is illustrated in Fig. 3, which illustrates the problem of finding
simultaneous equality of mission opportunities and risk limits for
women and men. We can offer several possible alternative approaches to
the NAS recommendation that would ensure safety and health of indi
vidual and that uncertainties and open science issues are not ignored,
while ensuring significant and equal opportunity:
• Limit crew independent of age and sex to 3 space missions made-up
of ISS increments and short duration lunar missions. This would also
reduce the individual’s cumulative risk of flight related LOC and
allow flight opportunities for a greater number of persons indepen
dent of age and sex or other factors.
• Use the up-to-date NSCR model to evaluate sex-averaged risks and
uncertainties thereby keeping the age dependence of risks, but not
ignoring uncertainties in risk projections. The age dependence of risk
includes components related to finite lifespan due to all cause of
death in a population (e.g. the U.S. population), and age dependent
radiation sensitivity found in epidemiological studies.
• The preceding approach could be implemented within the NSCR
approach with or without consideration of risk probability distri
butions as illustrated in Fig. 3. Here by applying the same principles
used for the joint distribution of males and females to separate risk
probabilities for males and females, such as the ones shown in Fig. 2
above. Let rM be the most probable risk for males, and rF be the most
probable risk for females, with σM and σF the corresponding 95%
width of each distribution. Then, without violating current ap
proaches, NASA could set separate limits for rM and rF, using the
different widths for permissible exposure.
3. Discussion of NAS recommendation #5
Recommendation #5: NASA should develop a protocol for
waiver of the proposed space radiation standard that is judicious,
transparent, and informed by ethics. To avoid the perception that
an exception to the standard is built into the space radiation
standard itself, NASA should follow the ethics decision framework
in developing a waiver protocol and it should provide supporting
analysis and explanation justifying any waiver to the standard.
Q7) Is a waiver process necessary when NASA management has the au
thority to increase limits to higher risk or exposure level? Is it ethical for a

Fig. 3. Illustration of differences in considerations of the risk of exposure induced death (REID) versus opportunities for females and males. The left panel illustrates a
consideration with uncertainties ignored, while the right panel shows considerations with uncertainty bands displayed. Opportunities are represented as “Safe Days
in Space”. NASA and NAS are considering approaches to balance this conundrum of competing view-points on astronaut risks.
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waiver to be issued by an employer that permits an employee to incur lifethreatening risks?
The current NAS report suggests a waiver process should be devel
oped for space exploration missions that would exceed the recom
mended effective dose limit. Our main concerns with this
recommendation are that the NCRP Report 167 (NCRP 2010) has stated
a waiver process is prohibited under U.S. Law, and we suggest the
combination of the proposed effective dose limit and a waiver process is
equivalent to NASA withdrawing from radiation limits for astronauts.
The NCRP Report 167 stated that the “assumption of risk” defense is
barred by the U.S. Federal Employment Compensation Act (FECA), and
is not needed as NASA management is authorized to modify the dose (or
risk) limit for specific missions. Notably the NAS report (National
Academy of Sciences 2021) does not discuss NCRP Report 167 findings
with respect to a potential waiver process. Quoting from NCRP Report
167 (NCRP 2010):

training in radiation safety, and pass written tests that must be renewed
every 2 years. During their work near the accelerator beam-lines all
researchers wear dosimeters. In the 25 years since NASA funded
research began at BNL not a single person has received a dose over 1 mSv
per year, which is a negligible dose compared to a single ISS mission
where average doses are 80 mSv per 6-month mission (Cucinotta et al.,
2008). In fact, the population dose for all NASA funded researchers to
BNL (typically ~50 persons per year) over many years is likely lower
than the average ISS mission dose for a single astronaut, while the
number of hours of training is many orders or magnitude larger.
We recommend that training on radiation protection, including
knowledge of heavy ion radiation biology, heavy ion physics and
epidemiology, with administration of a written test be part of the
astronaut candidate selection process. Rather than updated training for
crew on specific missions, we recommend that training of all astronauts
with information on the most recent radiobiology findings occur every
2-years. This level of training would increase awareness throughout the
astronaut community, and it would be beneficial if adult family and
loved ones of astronauts were allowed to receive the identical infor
mation presented in training lectures and written material developed.

As a matter of public policy, most courts have reasoned that an em
ployee’s expressed or implied assumption of risk will not be given effect
because of the unequal bargaining power between the employer and
employee and the economic necessity under which the employee is
required to assume the risk. Therefore, an employee is protected against
an unreasonable employment contract and against any harm resulting
from his or her employer’s negligence. Consent by an employee to
continue working on a task made dangerous by an employer’s negligence
is commonly called “assumption of risk.” In employer and employee re
lationships, the assumption of risk defense is barred by most Workmen’s
Compensation Acts, such as FECA.

5. Comparisons to past NAS/NRC and NCRP recommendations
The recent NAS report (National Academy of Sciences 2021) diverges
substantially from past recommendations to NASA by the NCRP or the
NAS, National Research Council (NRC). Cucinotta summarized major
recommendations in several publications (Cucinotta, 2014; Cucinotta
et al., 2015) which we list here. He notes, “Key recommendations with
respect to NASA’s regulatory framework for radiation limits, levels of
acceptable risk, and approaches to manage uncertainties in risks esti
mates were delivered in several NCRP and NAS reports of the past. In
1989 the NCRP (NCRP 1989) discussed three types of comparisons of
space radiation risks to other risks to form the basis for an acceptable
lifetime risk level for space radiation exposure: 1) to limits for
ground-based radiation workers, 2) to accidental deaths in the ’safe’,
’less-safe’, and ’hazardous’ occupations, and 3) to other accidental fa
tality risks faced by crew-members. Ground-based radiation workers
have lifetime radiation risks no greater than risks experienced on
average in the ’safe industries’, which was estimated as 0.5% in 1989
(NCRP 1989). However, the dose limits for ground-based radiation
workers were similar to the accidental deaths probability in the “less-
safe industries” where life-time risks of up to 3% were estimated at that
time. The NCRP noted that because astronauts face other occupational
fatality risks, comparison of radiation limits to life-time fatality risks in
’hazardous industries’ was not appropriate. Based on these observa
tions, the NCRP recommended NASA use a 3% lifetime fatality risk as
the basis for dose limits, and for the use of epidemiology based models to
estimate age at exposure and sex specific dose limits for astronauts
working in LEO (NCRP 1989). NASA implemented the NCRP recom
mended sex and age-at-exposure specific dose limits in 1990.”
In summarizing NCRP Report 132 published in 2000 (NCRP 2000),
Cucinotta notes, “Within a decade of the publication of NCRP Report No.
98, the NCRP reported that the comparison of space radiation risks to the
’less-safe industries’ no longer supports a 3% fatality risk as a basis for
radiation dose limits, because of the improvements in safety leading to
lower fatality rates in ground-based occupations. The comparison to
less-safe industries would lead to a lower acceptable risk level and stated
(NCRP 2000): The NCRP now considers the comparison with lifetime risk
associated with the occupational exposure limits recommended for workers
on the ground to be the most direct and the most valid. Consequently, the
NCRP recommends that the excess lifetime fatal cancer risk due to the ra
diation exposure of space workers for missions in LEO be limited to 3% excess
mortality and that this be the basis for career limits. Indeed improvements
in ground-based occupational safety since 1989 have occurred with
average lifetime fatality risks in most less-safe industries now below 1%
(National Safety Council 2011).”

We note that if there is indeed an exception to the U.S. labor laws
noted by NCRP as applied to astronauts, it is not described in the NAS
Report (National Academy of Sciences 2021). If in contrast to the NCRP
Report 167 discussion on illegality (NCRP 2010), that waivers are
possible, we point out an ethical problem if they were to be issued by
NASA. This is fundamentally unethical because it creates a mechanism
whereby NASA may inadvertently decide to subject an employee to
potentially serious harm. The ethical way to proceed with a waiver is it
should be granted by an authority independent of the employer and the
employee, that has examined the interests of all individuals affected
(including family, friends, and the public). This is typically done by
properly functioning Institutional Review Boards
4. NAS recommendation #6
Recommendation #6: NASA should conduct research to develop
evidence-based risk communication and the agency should
develop a radiation risk communication research agenda to fill
knowledge gaps such as (1) what information astronauts want; (2)
how astronauts process risk information; and (3) who/what are the
most effective sources of information for astronauts. In addition,
NASA should carry out research to examine and improve the
effectiveness of its current and proposed risk communication
strategies and materials.
Q8) What are risk communication processes, especially for missions
involving large radiation health risks?
One other observation that we were concerned with involves the
discussion in the NAS Reports on risk communication and training of
astronauts. We agree with the NAS Report (National Academy of Sci
ences 2021) discussion that the use of a stop-light to inform astronauts of
their radiation risks is severely over-simplified compared to the level of
potential risk to be encountered for several mission scenarios. In this
area we have a comparison to researchers that traveled to the Depart
ment of Energy’s, Brookhaven National Laboratory (BNL) to conduct
experiments with heavy ions at the Alternating Gradient Synchrotron
(AGS) and the NASA Space Radiation Laboratory (NSRL). Researchers
are required to follow strict safety procedures, undergo extensive
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The Institute of Medicine (IOM) of NAS noted in their 2001 Safe
Passage report (NAS-IOM 2001) and re-affirming an earlier SSB report
(NCRP 1998), “Until the radiation hazards to astronauts can be
controlled or otherwise mitigated by physical shielding, a 1998 National
Research Council report states, ‘long-duration space travel should be
postponed (SSB and NRC, 1998)’. Even if an effective physical radiation
shield is developed, it in no way diminishes the need for clinical study,
including monitoring of crewmembers’ exposures, long-term medical
follow-up, and the development of preventive medical treatments to make
astronauts more resistant to deep space-induced radiation damage”. In
reviewing the NASA Permissible Exposure Limits (PELs), which stated
the career radiation limit of 3% Risk of Exposure Induced Death (%
REID) at the 95% confidence level (CL), the NRC noted (NRC 2008),
“The committee strongly recommends that the permissible exposure limits
specified in the current NASA radiation protection standards not be violated
to meet engineering resources available at a particular level of funding.”
Cucinotta notes, “These external safety recommendations to NASA were
focused on deep space missions, however it is shown in this report that
similar concerns hold for multiple or long-term (1 year or longer) ISS
missions especially for missions near solar minimum were dose-rates
dominated by GCR can approach 1 mSv/day and about 2-fold higher
than missions near solar maximum for similar ISS altitudes.”
The NCRP Commentary-23 (NCRP 2014) published in 2014, sup
ported the use of the NSCR model for evaluation of risks for both ISS and
short-term lunar missions. The principle of as low as reasonably
achievable (ALARA) is applied after radiation limits are already pro
jected to be met to further reduce exposures and risk. ALARA is in
essence a call for an ongoing negotiation prior and during a mission to
reduce radiation exposure; a negotiation between health and safety
experts with mission directors and engineers controlling a mission, who
have potential competing conflicts of interest. A large focus of the NCRP
Commentary was on possible efforts to implement ALARA, however we
suggest ALARA efforts would have a reduced effectiveness with a waiver
process eliminating radiation limits in-place at NASA.

radiation risks would logically not only lead to approaches to reduce
uncertainties and develop counter-measures, but also to the determi
nation of the level of countermeasures needed to obtain acceptable risk
levels for exploration mission female and male crew.
We support the notion that men and women should have the same
opportunities for professional advancement, and each should under
stand clearly what is scientifically known about the potential combined
hazards in their mission, and what levels of risk uncertainties exist in
their estimation. However, it is a fundamental fact of nature that men
and women, exposed to the same quantity and/or quality of radiation,
do not always incur the same risks, or the same combined risks (e.g., to
microgravity and radiation) to each tissue type or physiological system
in the body. The NAS report, while concurring with the equal oppor
tunity requirement, fails to address the consequence of their recom
mendations that leads to unequal risks for men and women and that,
therefore, NASA risk management has to accept different limits or, if
they exist, compensating countermeasures for each.
It is necessary to emphasize that limits on radiation exposure are
calculated predictions for any given mission and that a waiver would
have to be issued prior to any mission for which the predicted risk ex
ceeds accepted limits. If radiation exposure during a mission exceeds
the calculated risk for that mission, such as might be caused by an un
expected solar event during an extra-vehicular activity (EVA), the
rationale for aborting or not the mission needs to be documented, and
the unplanned radiation incident (or accident) needs to be investigated
by proper procedures, but should not be dismissed with a waiver.
In addition, due to HIPAA privacy rules, both the NASA and the NAS
report ignore individual differences among females of the same age,
such as ethnic background, sexual activity, childbearing history, as well
as other differences that apply to both men and women such as, body
mass, muscle tone, medical history, lifestyle choices such as smoking,
alcohol or drug use, and other factors leading to possibly large interindividual differences in the risks incurred by exposure to radiation in
space. More generally, the use of a generic “35-year old female” to
replace consideration of the individual risk of every astronaut is a crit
ical break with well-established risk management practices that have
been vetted by responsible international advisory groups for many
decades.
Based on NCRP Report No. 167 (NCRP 2010) it is not clear that
employees such as astronauts can sign waivers to assume risks such as
severe morbidity or death due to radiation exposure under current U.S.
Labor Laws. Beyond this potential barrier, an unstated assumption made
in the discussion of waivers is that they may be issued by NASA. This is
fundamentally unethical, since it allows NASA to decide that an astro
naut may be exposed to any quantity of radiation and violates the
assumption of risk constraints. The only ethical way to proceed with a
waiver is if it is granted by an authority independent of the employer and
the employee, that has examined the interests of all individuals affected
(including family, friends, and the public) as is done by properly func
tioning Institutional Review Boards. By recommending that NASA
“develop a protocol for waivers” the NAS panel has relinquished its duty
to provide solid ethical guidance with oversight, regardless of the
qualification that it be “judicious, transparent, and informed by ethics.”

6. Conclusions
In conclusion, we find that the NAS Report under-values or ignores
information that suggests risks could be quite high and takes a giant leap
backwards through a proposed effective dose limit, and a waiver process
that is likely to lead to violation of each of the three principles of radi
ation protection.
The current radiation limits would not prevent female astronauts
from participating in largely all missions planned for the current decade,
while sufficient investments in the near-term could help to more
completely understand risks for missions in the next decade. We also
recommend that the relative level of investments in radiation protection
and radiobiology be comparable to other flight safety issues being
analyzed in-light of the similar fatality risk that could be allowed by
NASA and should be openly reported to the public.
Considering uncertainties in projection models of GCR suggests both
male and female astronauts could exceed a 3% fatality risk for a 600 mSv
effective dose, and possibly incur clinically significant deterministic
effects (tissue reactions). Therefore, we disagree with the NAS recom
mendation to ignore uncertainties in risk projections, which would also
contradict earlier recommendations by the NCRP and NAS. Uncertainty
analysis has progressed in recent years in that we can focus on specific
issues that need to be addressed; non-targeted effects, the possible
higher lethality of tumors produced by high LET radiation, tissue spe
cific risk assessments, cognitive detriments, circulatory diseases, and
possibility of leukemia’s and vision impairing cataracts during long
space missions. NASA should make sufficient investments to understand
risks and reduce uncertainties in these areas, while discovering possible
countermeasures. The knowledge to understand these aspects of space

Declaration of Competing Interest
None.
Acknowledgements
The contents of this paper are the independent opinions of the au
thors, and do not represent the positions or policies of their individual
institutional affiliations.

68

F.A. Cucinotta et al.

Life Sciences in Space Research 31 (2021) 59–70

References

Hoel, D.G., 2015. Comments on the DDREF estimate of the BEIR VII committee. Health
Phys. 108, 351–356.
Schimmerling, W., Cucinotta, F.A., 2006. Dose and dose-rate effectiveness of space
radiation. Radiat. Prot. Dosim. 122, 349–353.
Cucinotta, F.A., Nikjoo, H., Goodhead, D.T., 1998. Comment on the effects of delta-rays
on the number of particle-track transversals per cell in laboratory and space
exposures. Radiat. Res. 150, 115–119.
Plante, I., Cucinotta, F.A., 2008. Ionization and excitation cross sections for the
interaction of HZE particles in liquid water and application to Monte-Carlo
simulation of radiation tracks. New J. Physics 10, 1–15.
Storer, J.B., Mitchell, T.J., Fry, R.J.M., 1988. Extrapolation of the relative risk of
radiogenic neoplasms across mouse strains and to man. Radiat. Res. 114, 331–353.
Kim, M.Y., Cucinotta, F.A., Nounu, H., Zeitlin, C., Hassler, D.M., Rafkin, S.C.R., et al.,
2014. Comparison of martian surface ionizing radiation measurements from MSLRAD with Badhwar-O’Neill 2011/HZETRN model calculations. J. Geophys. Res. 119
https://doi.org/10.1002/2013JE004549.
Kim M.Y., Rusek A., Cucinotta F.A. Issues in ground-based GCR simulation for space
radiobiology. Front Radiat. Oncol. 10.3389/fonc.2015.00122, 2015.
Coggle, J.E., 1988. Lung tumour induction in mice after X-rays and neutrons. Int. J.
Radiat. Biol. 53, 585–598.
Ullrich, R.L., Jernigan, M.C., Cosgrove, R., et al., 1976. The influence of dose and dose
rate on the incidence of neoplastic disease in RFM mice after neutron irradiation.
Radiat. Res. 68, 115–131.
Ullrich, R.L., Jernigan, M.C., Storer, J.B., 1977. Neutron carcinogenesis. dose and doserate effects in Balb/c mice. Radiat. Res. 72, 487–498.
Fry, R.J.M., 1981. Experimental radiation carcinogenesis: what have we learned? Radiat.
Res. 87, 224–239.
NCRP, Relative biological effectiveness of radiations of different quality. National
Council on Radiation Protection and Measurements Report 104, Bethesda MD, 1990.
Illa-Bochaca, I., et al., 2014. Densely ionizing radiation acts via the microenvironment to
promote aggressive Trp53-null mammary carcinomas. Cancer Res. 74, 7137–7148.
Omene, C., et al., 2020. Aggressive mammary cancers lacking lymphocytic infiltration
arise in irradiation mice and can be prevented by dietary intervention. Cancer
Immun. Res. 8, 217–229.
Gueguinou, N., et al., 2009. Could spaceflight-associated immune system weakening
preclude the expansion of human presence beyond earth’s orbit? J. Leukoc. Biol. 86,
1027–1038.
Akiyama, T., et al., 2020. How does spaceflight effect the acquired immune system?
Nature Micrograv. 6, 14.
Mishra, B., et al., 2018. Charged-iron-particles found in galactic cosmic rays are potent
inducers of epithelial ovarian tumors. Radiat. Res. 190, 142–150.
Schimmerling, W., 2010. Accepting space radiation risks. Radiat. Environ. Biophys. 49,
325–329.
Maxwell, C.A., et al., 2008. Targeted and nontargeted effects of ionizing radiation that
impact genomic instability. Cancer Res. 68, 8304–8311.
Kadhim, M., et al., 2013. Non-targeted effects of ionizing radiation- implications for low
dose risk. Mutation Res. 752, 84–98.
Lorimore, S.A., Coates, P.J., Wright, E.G., 2003. Radiation-induced genomic instability
and bystander effects: inter-related nontargeted effects of exposure to ionizing
radiation. Oncogene 22, 7058–7069.
Barcellos-Hoff, M.H., Mao, J., 2016. HZE radiation nontargeted effects on the
microenvironment that mediate mammary carcinogenesis. Front. Oncol. 6, 57.
Hada, M., Chappell, L.J., Wang, M., George, K.A., Cucinotta, F.A., 2014. On the induction
of chromosomal aberrations at fluence of less than one HZE particle per cell nucleus.
Radiat. Res. 182, 368–379.
Nagasawa, H., Little, J.B., 1992. Induction of sister chromatid exchanges by extremely
low doses of alpha-particles. Cancer Res. 52, 6394–6396.
Belyakov, O.V., Mitchell, S.A., Parikh, D., et al., 2005. Biological effects in unirradiated
human tissue induced by radiation damage up to 1 mm away. Proc. Natl Acad. Sci.
USA 102, 14203–14208.
Chang, P.Y., Cucinotta, F.A., Bjornstad, K.A., et al., 2016. Harderian gland tumorigenesis:
low-dose- and LET-response. Radiat. Res. 185, 448–459.
Fry, R.J.M., Powers-Risius, P., Alpen, E.L., Ainsworth, E.J., 1985. High LET radiation
carcinogenesis. Radiat. Res. 104, S188–S195.
Alpen, E.L., Powers-Risius, P., Curtis, S.B., DeGuzman, R., 1993. Tumorigenic potential
of high-Z, high-LET charged particle radiations. Radiat. Res. 88, 132–143.
Weil, M.M., Bedford, J.S., Bielefeldt-Ohmann, H., Ray, A.F., Gernik, P.C., Ehrhart, E.J.,
et al., 2009. Incidence of acute myeloid leukemia and hepatocellular carcinoma in
mice irradiated with 1 GeV/nucleon 56Fe ions. Radiat. Res. 172, 213–219.
Weil, M.M., Ray, F.A., Genik, P.C., Yu, Y., McCarthy, M., Fallgren, C.M., et al., 2014.
Effects of 28Si ions, 56Fe ions, and protons on the induction of murine acute myeloid
leukemia and hepatocellular carcinoma. PLoS ONE 9 (8), e104819.
Grahn, D., Lombard, L.S., Carnes, B.A., 1992. The comparative tumorigenic effects of
fission neutrons and Cobalt-60 γ rays in B6CF1 mouse. Radiat. Res. 129, 19–36.
Imaoka, T., Nishimura, Kakinuma S, Hatano, Y., Ohmachi, Y., Yoshinaga, S., et al., 2007.
High relative biological effectiveness of carbon ion irradiation on induction of rat
mammary carcinoma and its lack of H-ras and Tp53 mutations. Int. J. Radiat. Oncol.
Biophys. 69, 194–203.
Trani, D., Datta, K., Doiron, K., Kallakury, B., Fornace Jr, A.J, 2010. Enhanced intestinal
tumor multiplicity and grade in vivo after HZE exposure: mouse models for space
radiation risk estimates. Radiat. Environ. Biophys. 49, 389–396.
Datta, K., Suman, S., Kallakury, B.V., Fornace Jr, A.J, 2013. Heavy ion radiation exposure
triggered higher intestinal tumor frequency and greater β-catenin activation than
γ-radiation in APC Min/+ mice. PLoS ONE 8, e59295.

National Academy of Sciences, 2021. Space radiation and astronaut health: Managing
and communicating risk. National Academy Press, Washington D.C.
Cucinotta, F.A., Kim, M.Y., Chappell, L., 2013a. Space radiation cancer risk projections
and uncertainties- 2012. NASA TP, pp. 2013–217375.
Cucinotta, F.A., Kim, M.Y., Chappell, L., Huff, J.L., 2013b. How safe is safe enough?
radiation protection for a human mission to Mars. PLoS ONE 8 (10), e74988.
Cucinotta, F.A., 2014. Space radiation risks for astronauts on multiple International
Space station missions. PLoS ONE 9 (4), e96099.
Cucinotta, F.A., 2015. A new approach to reduce uncertainties in space radiation cancer
risk predictions. PLoS ONE 10 (3), e0120717.
Cucinotta, F.A., Alp, M., Rowedder, B., Kim, M.Y., 2015. Safe days in space with
acceptable uncertainty from space radiation exposure. Life Sci. Space Res. 2, 54–69.
Cucinotta, F.A., Cacao, E., Alp, M., 2016. Space radiation quality factors and the deltaray dose and dose-rate effectiveness factor. Health Phys. 110, 262–266.
Cacao, E., Hada, M., Saganti, P.B., George, K.A., Cucinotta, F.A., 2016. Relative
biological effectiveness of HZE particles for chromosomal aberrations and other
surrogate cancer risk endpoints. PLoS ONE 11 (4), e0153998.
Cucinotta, F.A., To, K., Cacao, E., 2017. Predictions of space radiation fatality risk for
exploration missions. Life Sci. Space Res. 13, 1–11.
Cucinotta, F.A., Cacao, E., 2017. Non-targeted effects models predict significantly higher
Mars mission cancer risk than targeted effects model. Scientific Rep. 7, 1832.
Cucinotta, F.A., Cacao, E., Kim, M.Y., Saganti, P.B., 2018. Non-targeted effects lead to a
paradigm shift in risk assessment for a mission to the Earth’s moon or martian moon
phobos. Radiat. Protect Dosim. 183, 213–218.
Cucinotta, F.A., Cacao, E., Kim, M.Y., Saganti, P.B., 2020a. Cancer and circulatory
disease risks for a human mission to Mars: Private mission considerations. Acta
Astronaut. 166, 529–536.
Cucinotta, F.A., Cacao, E., Kim, M.Y., Saganti, P.B., 2020b. Benchmarking risk
predictions and uncertainties in the NSCR model of GCR cancer risks with revised
low LET risk coefficients. Life Sci. Space Res. 27, 64–73.
NAS, 1970. Radiation protection guides and constraints for space-mission and vehicledesign studies involving nuclear systems. Natl. Acad. Press, Washington, D. C.
NAS, 1996. Radiation hazards to crews on crews on interplanetary missions. Natl. Acad.
Press, Washington, D. C.
NRC, 2008. Managing space radiation risk in the new era of space exploration. National
research council, aeronautics and engineering board. The National Academies Press,
Washington D.C.
NRC, 2012. Technical evaluation of the NASA model for cancer risk to astronauts due to
space radiation. National research council. The National Academies Press,
Washington D.C.
NAS-IOM, 2001. National academy of sciences institute of medicine safe passage:
Astronaut care for exploration missions. The National Academies Press, Washington
D.C.
NRC, 1998. National research council space science board, a strategy for research in
space biology and medicine in the new century. The National Academy Press,
Washington D.C.
NCRP, 1989. Guidance on radiation received in space activities. NCRP Rep. National
Council on Radiation Protection and Measurements, Bethesda, MD, p. 98.
NCRP, 2000. Recommendations of dose limits for low EARTH orbit. NCRP Report.
National Council on Radiation Protection and Measurements, Bethesda MD, p. 132.
NCRP. Information needed to make radiation protection recommendations for space
missions beyond low EARTH orbit. NCRP Report 153: Bethesda MD, 2006.
NCRP, 2014. Radiation protection for space activities: Supplement to previous
recommendations. National Council on Radiation Protection and Measurements
Commentary, Bethesda MD, p. 23.
NCRP, 1997. Acceptability of risk from radiation—application to human spaceflight.
Symp. Proc. National Council on Radiation Protection and Measurements, Bethesda
Md, p. 3.
NCRP, 2010. National council of radiation protection and measurements report no 167.
Potential Impact of Individual Genetic Susceptibility and Previous Radiation
Exposure On Radiation Risk For Astronauts. NCRP, Bethesda Md.
Aerospace Safety Advisory Panel, Annual report for 2010. http://oiir.hq.nasa.gov/asap/
documents/2010_ASAP_Annual_Report.pdf. Accessed 2013 .
Grant, E.J., Brenner, A.V., Sugiyama, H., et al., 2017. Solid cancer incidence among the
Life-span study of atomic-bomb survivors: 1958-2009. Radiat. Res. 187, 513–537.
Brenner, A.V., et al., 2018. Incidence of breast cancer in the life span study of atomic
bomb survivors: 1958-2009. Radiat. Res. 190, 433–444.
Leuraud, K., Richardson, D.B., Cardis, E., Daniels, R.D., Gillies, M., et al., 2015. Ionising
radiation and risk of death from leukaemia and lymphoma in radiation-monitored
workers (INWORKS): an international cohort study. Lancet Haematol. 2, e276.
Richardson, D.B., Cardis, E., Daniels, R.D., Gillies, M., O’Hagan, J.A., et al., 2015. Risk of
cancer from occupational exposure to ionizing radiation: retrospective cohort study
of workers in Frances, the United Kingdom, and the United States (INWORKS). Brit.
Med. J. 351, h5359.
Richardson, D.B., Cardis, E., Daniels, R.D., Gillies, M., Haylock, R., et al., 2018. Sitespecific solid cancer mortality after exposure to ionizing radiation. Epidemiology 29,
31–40.
Goodhead, D.T., Nikjoo, H., 1989. Track structure analysis of ultrasoft X-rays compared
to high- and low-LET radiations. Int. J. Radiat. Biol. 55, 513–529.
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al., 2021. Cancer statistics, 2021. CA: A Cancer J.
Clin. 71, 7–33.
BEIR, VII, 2006. Health risks from exposure to low levels of ionizing radiation. National
academy of sciences committee on the biological effects of radiation. National
Academy of Sciences Press, Washington DC.

69

F.A. Cucinotta et al.

Life Sciences in Space Research 31 (2021) 59–70
Takahashi, I., et al., 2017. Heart disease mortality in the life space study, 1950–2008.
Radiat. Res. 187, 319–332.
Pham, T., et al., 2013. Radiation exposure and the risk of mortality from noncancer
respiratory diseases in the life span study, 1950–2005. Radiat. Res. 180, 539–545.
Cucinotta, F.A., et al., 2001. Space radiation and cataracts in astronauts. Radiat. Res.
156, 460–466.
Chylack, L.T., et al., 2009. NASCA Report 1: cross-sectional study of relationship of
exposure to space radiation and risk of lens opacity. Radiat. Res. 172, 10–20.
NASA Internal Report, Recommendations of the NASA External Research and Clinical
Advisory Panel (RCAP) For Radiation, Houston TX, 2015.
Suman, S., Kumar, S., Moon, B.H., et al., 2016. Relative biological effectiveness of
energetic heavy ions for intestinal tumorigenesis shows male preponderance and
radiation type and energy dependence in APC 1638 N/+ mice. Int. J. Radiat. Oncol.
Biol. Phys. 95, 131–138.
Locke, P.A., Weil, M.M., 2016. Personalized cancer risk assessments for space radiation
exposures. Front. Oncol. 38.
Cucinotta, F.A., Kim, M.H., Willingham, V., George, K.A., 2008. Physical and biological
organ dosimetry analysis for International Space Station astronauts. Radiat. Res.
170, 127–138.
Clayton, J.A., 2018. Applying the new SABV (sex as a biological variable) policy to
research and clinical care. Phys. & Behav. 187, 2–5.
National Safety Council Injury Facts 2011 Edition. National Safety Council: Itasca IL,
2011.

Wang, X., Farris, A.B., Wang, P., Zhang, X., Wang, H., Wang, Y., 2015. Relative
effectiveness at 1 Gy after acute and fractionated exposures of heavy ions with
different linear energy transfer for lung tumorigenesis. Radiat. Res. 18 (2), 233–239.
Cucinotta, F.A., Cacao, E., 2019. Risks of cognitive detriments after low dose heavy ion
and proton exposures. Int. J. Radiat. Biol. 95, 985–998.
Parihar, V.K., et al., 2016. Cosmic radiation exposure and persistent cognitive
dysfunction. Sci. Rep. 34773.
Parihar, V.K., et al., 2015. What happens to your brain on the way to Mars? Sci. Adv. 1,
e1400256.
Britten, R.A., Jewell, J.S., Duncan, V.D., Davis, L.K., Hadley, M.M., Wyrobek, A.J., 2017.
Spatial memory performance of socially mature Wistar rats is impaired after
exposure to low (5cGy) doses of 1 GeV/n 48Ti particles. Radiat. Res. 187, 60–65.
Raber, J., Weber, S.J., Kronenberg, A., Turker, M.S., 2016. Sex- and dose dependent
effects of calcium ion irradiation on behavioral performance of B6D2F1 mice during
contextual fear conditioning training. Life Sci. Space Res. 9, 56–61.
Parihar, V.K., et al., 2020. Sex-specific cognitive deficits following space radiation
exposure. Front. Behav. Neurosci. 14, 535885.
Liu, B., et al., 2018. Space-like 56Fe irradiation manifests mild, early sex-specific
behavioral and neuropathological changes in wildtype and Alzheimer’s-like
transgenic mice. Sci. Rep. 9, 12118.
Azizova, T.V., et al., 2020. Occupational exposure to chronic ionizing radiation increases
risk of Parkinson’s disease incidence in Russian Mayak workers. Int. J. Epidem. 49,
435–447.
Little, M., Azizova, D., Bazyka, S.D., Bouffler, E., Cardis, S., et al., 2012. Environ. Health
Persp. 120, 453–454.

70

